Immunocytokines are a promising immunotherapeutic approach against glioblastoma
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Immunocytokines display promising antitumor activity in orthotopic mouse models of glioma and patients with glioblastoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specific antibodies (such as L19) against fibronectin to improve tumor response in the clinical trials of patients with glioblastoma by localizing interleukin 2 (IL‐2) or interleukin 12 (IL‐12) in the tumor, leading to increased infiltration of cytotoxic T cells [81, 82, 83].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [81]
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“This might be the consequence of glioma cell–intrinsic factors, such as cell-to-cell heterogeneity (5) and the presence of too few immunogenic neoepitopes (6), as well as high levels of immunosuppressive cytokines (7) and immunosuppressive myeloid (8) and lymphoid (9) cell populations, which result in a strong immunos…”
BackgroundAn Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Self-citationWeller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Self-citationWeller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationThe making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationChang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Cited by
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Self-citationCurrent advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Challenges in glioblastoma research: focus on the tumor microenvironment
Bikfalvi, A., da Costa, C. A., Avril, T., Barnier, J.-V., Bauchet, L., Brisson, L., Cartron, P. F., Castel, H., Chevet, E., Chneiweiss, H., et al. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.09.005 · Cited by 302
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Zheng, X., Wu, Y., Bi, J., Huang, Y., Cheng, Y., Li, Y., Wu, Y., Cao, G., & Tian, Z. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00786-6 · Cited by 167
Wen, P. Y., Weller, M., Lee, E. Q., Touat, M., Khasraw, M., Rahman, R. M., Platten, M., Lim, M. K., Winkler, F., Horbinski, C., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf177 · Cited by 133
Self-citationUnderstanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Mair, M. J., Bartsch, R., Rhun, É. L., Berghoff, A. S., Brastianos, P. K., Cortés, J., Gan, H. K., Lin, N., Lassman, A. B., Wen, P. Y., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00756-z · Cited by 120
Self-citationLi, Z., Fu, W., Chen, X.-Q., Wang, S., Deng, R.-S., Tang, X., Yang, K., Niu, Q., Zhou, H., Li, Q., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02291-8 · Cited by 113
Immunotherapy in glioblastoma treatment: Current state and future prospects
Pinheiro, S. L. R., Lemos, F. F. B., Marques, H. S., Luz, M. S., Silva, L. G. D. O., dos Santos, C. F. S. M., Evangelista, K. D. C., Calmon, M. S., Loureiro, M. S., & de Melo, F. F. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i4.138 · Cited by 111
Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments
Feldman, L. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384249 · Cited by 103
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme
Aldoghachi, A. F., Aldoghachi, A. F., Breyne, K., Ling, K., & Cheah, P.-S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.030 · Cited by 102
Alghamri, M. S., McClellan, B. L., Hartlage, C. S., Haase, S., Faisal, S. M., Thalla, R., Dabaja, A. A., Banerjee, K., Carney, S. V., Mujeeb, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680021 · Cited by 99
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
Guo, J., Liang, Y., Xue, D., Shen, J., Cai, Y., Zhu, J., Fu, Y., & Peng, H. (2021) · Cell Research · doi:10.1038/s41422-021-00543-4 · Cited by 96
Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Meister, H., Look, T., Roth, P., Pascolo, S., Sahin, U., Lee, S., Hale, B. D., Snijder, B., Regli, L., Ravi, V. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4384 · Cited by 87
Self-citationTurco, V., Pfleiderer, K., Hunger, J., Horvat, N. K., Jazi, K. K., Schregel, K., Fischer, M. D., Brugnara, G., Jähne, K., Sturm, V. J. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36321-6 · Cited by 91
Next-generation cytokines for cancer immunotherapy
Xue, D., Hsu, E. J., Fu, Y., & Peng, H. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab014 · Cited by 96
Hicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications · doi:10.1038/s41467-021-25393-x · Cited by 83
Alim, L., Keane, C., & Souza-Fonseca-Guimarães, F. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102409 · Cited by 84
Cytokine engineering for targeted cancer immunotherapy
Bonati, L., & Tang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.007 · Cited by 85
EMP3 mediates glioblastoma‐associated macrophage infiltration to drive T cell exclusion
Chen, Q., Jin, J., Huang, X., Wu, F., Huang, H., & Zhan, R. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01954-2 · Cited by 84
Catania, G., Rodella, G., Vanvarenberg, K., Préat, V., & Malfanti, A. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122006 · Cited by 70
Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy
Ben‐Baruch, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903679 · Cited by 67
Engineered antibody fusion proteins for targeted disease therapy
Silver, A. B., Leonard, E. K., Gould, J. R., & Spangler, J. B. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.09.009 · Cited by 63
Faisal, S. M., Comba, A., Varela, M. L., Argento, A. E., Brumley, E. K., Abel, C. C., Castro, M. G., & Lowenstein, P. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005069 · Cited by 62
Immunocytes in the tumor microenvironment: recent updates and interconnections
Yu, J., Fu, L., Wu, R., Che, L., Liu, G., Ran, Q., Xia, Z., Liang, X., & Zhao, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517959 · Cited by 74
Look, T., Sankowski, R., Bouzereau, M., Fazio, S., Sun, M., Buck, A., Binder, N., Mastall, M., Prisco, F., Seehusen, F., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101931 · Cited by 62
Self-citationLook, T., Puca, E., Bühler, M., Kirschenbaum, D., Luca, R. D., Stucchi, R., Ravazza, D., Nitto, C. D., Roth, P., Katzenelenbogen, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf2281 · Cited by 46
Self-citationTherapeutic approaches to modulate the immune microenvironment in gliomas
Sarantopoulos, A., Ene, C., & Aquilanti, E. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00717-4 · Cited by 45
Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
MacDonald, A., Wu, T. ‐., & Hung, C. (2021) · Journal of Immunology Research · doi:10.1155/2021/7855808 · Cited by 44
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
Co-evolution of glioma and immune microenvironment
Elguindy, M. M., Young, J. S., Ho, W. S., & Lu, R. O. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009175 · Cited by 42
Li, J., Wang, X., Guo, Y., Zhang, Y., Zhu, A., Zeng, W., Di, L., & Wang, R. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.144692 · Cited by 40
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials
Tang, F., Tie, Y., Wei, Y.-Q., Tu, C., & Wei, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188606 · Cited by 42
Nanobiotechnology-based treatment strategies for malignant relapsed glioma
Qiu, Q., Ding, X., Chen, J., Chen, S., & Wang, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.016 · Cited by 39
Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
Qi, Z., Long, X., Liu, J., & Cheng, P. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.819363 · Cited by 37
Liu, F., Zhou, Q., Jiang, H., Zhang, T., Miao, C., Xu, X., Wu, J., Yin, S.-L., Shijie, X., Peng, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02686-1 · Cited by 36
Glioma–Immune Cell Crosstalk in Tumor Progression
Elguindy, M. M., Young, J. S., Mondal, I., Lu, R. O., & Ho, W. S. (2024) · Cancers · doi:10.3390/cancers16020308 · Cited by 35
Franson, A. T., McClellan, B. L., Varela, M. L., Comba, A., Syed, M. F., Banerjee, K., Zhu, Z., González, N., Candolfi, M., Lowenstein, P. R., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.966458 · Cited by 35
Garcia-Fabiani, M. B., Haase, S., Comba, A., Carney, S. V., McClellan, B. L., Banerjee, K., Alghamri, M. S., Faisal, S. M., Kadiyala, P., Núñez, F. J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.631037 · Cited by 32
Nadal, L., Peissert, F., Elsayed, A., Weiß, T., Look, T., Weller, M., Piro, G., Carbone, C., Tortora, G., Matasci, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005282 · Cited by 31
Self-citationImmunotherapy for brain metastases and primary brain tumors
Giacomo, A. M. D., Mair, M. J., Ceccarelli, M., Anichini, A., Ibrahim, R. A., Weller, M., Lahn, M., Eggermont, A. M. M., Fox, B. A., & Maio, M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.012 · Cited by 39
Self-citationVaccine-based immunotherapy and related preclinical models for glioma
Yao, L., Hatami, M., Ma, W., & Skutella, T. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.06.009 · Cited by 30
Protein isoform-centric therapeutics: expanding targets and increasing specificity
Kjer-Hansen, P., Phan, T. G., & Weatheritt, R. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01025-z · Cited by 30
EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401
Nam, Y. W., Shin, J.-H., Kim, S., Hwang, C. H., Lee, C.-S., Hwang, G., Kim, H.-R., Roe, J., & Song, J. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01316-3 · Cited by 28
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies
Ratnam, N. M., Sonnemann, H. M., Frederico, S. C., Chen, H. A., Hutchinson, M.-K. N. D., Dowdy, T., Reid, C. M., Jung, J., Zhang, W., Song, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719091 · Cited by 28
Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity
Hutóczki, G., Virga, J., Birkó, Z., & Klekner, Á. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810005 · Cited by 28
Advancements and challenges in immunocytokines: A new arsenal against cancer
Shi, W., Liu, N., & Lu, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.024 · Cited by 26
Jailkhani, N., Clauser, K. R., Mak, H. H., Rickelt, S., Tian, C., Whittaker, C. A., Tanabe, K. K., Purdy, S. R., Carr, S. A., & Hynes, R. O. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1532 · Cited by 22
Current status of precision oncology in adult glioblastoma
Weller, J. M., Potthoff, A., Zeyen, T., Schaub, C., Duffy, C., Schneider, M. B., & Herrlinger, U. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13678 · Cited by 23
Scapin, G., Çağdaş, E., Grav, L. M., Lewis, N. E., Goletz, S., & Hafkenscheid, L. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108467 · Cited by 19
Sun, M., Białasek, M., Mayoux, M., Lin, M.-S., Buck, A., Marszałek, I., Taciak, B., Bühler, M., Górczak, M., Kucharzewska, P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr4058 · Cited by 20
Self-citationThe War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?
da Silva, L. H. R., Catharino, L. C. C., da Silva, V. J., Evangelista, G. C. M., & Barbuto, J. A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020400 · Cited by 19
Facts and Hopes: Immunocytokines for Cancer Immunotherapy
Pabani, A., & Gainor, J. F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1837 · Cited by 18
Zhang, Y., Wang, S., Rha, H., Xu, C., Pei, Y., Ji, X., Zhang, J., Lu, R., Zhang, S., Xie, Z., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122696 · Cited by 18
An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease
Plaza, S. D., Lizak, C., Matasci, M., Mock, J., Villa, A., Neri, D., & Cazzamalli, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810020 · Cited by 18
Self-citationImmunocytokines in cancer treatment: A systematic review
Agliardi, S., Veronese, C., Panzeri, F., Palazzini, S., Guarnieri, G., Loiacono, S., Martinelli, V., Potenza, A. M., Sbraga, E., Rissotto, E., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102978 · Cited by 17
The Role of CD4+ T Cells in the Immunotherapy of Brain Disease by Secreting Different Cytokines
Wang, J., Nan, Y., Liu, M., & Hu, K. (2022) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-022-10056-5 · Cited by 16
Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy
Prodi, E., Neri, D., & Luca, R. D. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s480787 · Cited by 16
Self-citationNanoparticle approaches for manipulating cytokine delivery and neutralization
Wang, R., Kubiatowicz, L. J., Zhang, R., Bao, L., Fang, R. H., & Zhang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1592795 · Cited by 18
Turner, M. C., Radzikowska, U., Ferastraoaru, D. E., Pascal, M., Wesseling, P., McCraw, A. J., Backes, C., Bax, H. J., Bergmann, C., Bianchini, R., et al. (2024) · Allergy · doi:10.1111/all.15994 · Cited by 15
Self-citationRadiation immunodynamics in patients with glioblastoma receiving chemoradiation
Sloan, L., Sen, R., Liu, C., Doucet, M., Blosser, L., Katulis, L., Kamson, D. O., Grossman, S. A., Holdhoff, M., Redmond, K. J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1438044 · Cited by 14
Jiang, Z., Yang, N., Jin, J., Zhang, Z., Lu, H., Xu, L., Chen, Y., Jin, L., Zhou, L., Yang, H., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011642 · Cited by 14
Wang, D., Jiang, Y., Wang, T., Wang, Z., & Zou, F. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01261-5 · Cited by 15
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α
Corti, A., Calimeri, T., Curnis, F., & Ferreri, A. J. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071414 · Cited by 15
Pekar, L., Krah, S., & Zielonka, S. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2322062 · Cited by 13
Carbone, C., Luca, R. D., Puca, E., Agostini, A., Caggiano, A., Priori, L., Esposito, A., Ascrizzi, S., Piro, G., Salvatore, L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03238-x · Cited by 12
Self-citationMa, Z., Hao, X., Qu, S., Zhang, Q., Luo, J., Li, H., Liu, J., Dai, W., Li, J., Gu, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010580 · Cited by 12
Heterogeneity and individualized treatment of microenvironment in glioblastoma (Review)
Kang, W., Mo, Z., Li, W., Ma, H., & Zhang, Q. (2023) · Oncology Reports · doi:10.3892/or.2023.8654 · Cited by 11
Transcriptomic Landscape of Lower Grade Glioma Based on Age-Related Non-Silent Somatic Mutations
Park, Y., Park, J., Ahn, J. W., Sim, J. M., Kang, S. J., Kim, S., Hwang, S., Han, S., Sung, K. S., & Lim, J. (2021) · Current Oncology · doi:10.3390/curroncol28030210 · Cited by 12
A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors
Rotta, G., Gilardoni, E., Ravazza, D., Mock, J., Seehusen, F., Elsayed, A., Puca, E., Luca, R. D., Pellegrino, C. E., Look, T., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00034-0 · Cited by 10
Self-citationSong, L., Qi, G., Shi, W., Zeng, Q., Qin, Y., Wang, Z., Li, W., Song, Z., Zhang, A., & Lu, H. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011944 · Cited by 9
Zhou, S., Zhang, X., Lin, J., Fenfen, M., Chen, H., CHEN, J., & Luan, X. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.015 · Cited by 10
Nitto, C. D., Ravazza, D., Gilardoni, E., Look, T., Sun, M., Prodi, E., Moisoiu, V., Pellegrino, C. E., Manz, M. G., Puca, E., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008504 · Cited by 9
Self-citationNanobodies in cytokine‑mediated immunotherapy and immunoimaging (Review)
Zhang, X., Wang, J., Tan, Y., Chen, C.-T., Tang, S., Zhao, S., Qin, Q., Huang, H., & Duan, S. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5336 · Cited by 8
Lipid Nanocarriers as Precision Delivery Systems for Brain Tumors
Keshari, R., Dewani, M., Kaur, N., Patel, G. K., Singh, S. K., Chandra, P., Prasad, R., & Srivastava, R. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00007 · Cited by 8
Monaco, G., Khavaran, A., Gasull, A. D., Cahueau, J., Diebold, M., Chhatbar, C., Friedrich, M., Heiland, D. H., & Sankowski, R. (2022) · Cancers · doi:10.3390/cancers14194915 · Cited by 8
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties
Nitto, C. D., Gilardoni, E., Mock, J., Nadal, L., Weiß, T., Weller, M., Seehusen, F., Libbra, C., Puca, E., Neri, D., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020377 · Cited by 9
Self-citationSahm, K., & Weiß, T. (2024) · Der Nervenarzt · doi:10.1007/s00115-023-01590-5 · Cited by 8
Antibody drug conjugates for glioblastoma: current progress towards clinical use
Gan, H. K., Parakh, S., Osellame, L. D., Cher, L., Uccellini, A., Hafeez, U., Menon, S., & Scott, A. M. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2282729 · Cited by 8
A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
Shamshiripour, P., Nikoobakht, M., Mansourinejad, Z., Ahmadvand, D., & Akbarpour, M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2027759 · Cited by 7
Kumar, M., Nassour-Caswell, L. C., Alrefai, H., Anderson, J. C., Schanel, T. L., Hicks, P. H., Cardan, R., & Willey, C. D. (2024) · Cells · doi:10.3390/cells13231995 · Cited by 9
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21
Nitto, C. D., Neri, D., Weiß, T., Weller, M., & Luca, R. D. (2022) · Antibodies · doi:10.3390/antib11010019 · Cited by 7
Self-citationCytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy
Rotta, G., Puca, E., Cazzamalli, S., Neri, D., & Plaza, S. D. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00187 · Cited by 7
Self-citationRecent advances in biomimetic nanodelivery systems for the treatment of glioblastoma
Yuan, Z., Li, J., & Na, Q. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114668 · Cited by 7
Kundu, S., Mitra, S., Roshini, A., Longo, J. A., Longo, S. L., Venskus, A. G., Babu, H., & Viapiano, M. S. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0083 · Cited by 6
Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma
Zaidi, S. E., Moelker, E., Singh, K., Mohan, A. A., Salgado, M. A., Essibayi, M. A., Hotchkiss, K. M., Shen, S. H., Lee, W., Sampson, J. H., et al. (2023) · BioDrugs · doi:10.1007/s40259-023-00598-2 · Cited by 6
Jiang, Q., Wang, X., Yang, Q., Zhang, H., & Wang, X. (2021) · DNA and Cell Biology · doi:10.1089/dna.2020.6384 · Cited by 6
Granulocyte-macrophage colony-stimulating factor for newly diagnosed glioblastoma
Cao, C., Wang, L., Jiang, F., Jin, Q., Jin, T., Huang, S., Hu, Q., Chen, Y., Piao, Y., Hua, Y., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101156 · Cited by 4
Zhang, X., Yang, N., Tang, X., Liu, N., Lu, Q., Zhang, Z., Xu, L., Jiang, L., Ge, H., Lu, H., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07321-5 · Cited by 4
Nanomedicines: an update of diagnostic and therapeutic applications in multiple cancers
Shinde, S. J., Priyanka, Jakhar, M., Arora, I., Sehgal, D., Mahak, Kumari, A., Dhiman, T., Priya, Kumar, N., et al. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2613059 · Cited by 4
Immunocytokines in cancer immunotherapy: opportunities and challenges
Wang, S., Yao, L., Cai, J., Gao, H., & Zhou, F. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1716612 · Cited by 4
Liu, Y., Luo, M., Shi, Y., Guo, Y. J., Zhang, H., Yang, K., Li, T., Yang, L., Liu, T., Huang, B., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02393-9 · Cited by 4
Antibody-cytokine fusion breathes new life into glioblastoma therapy
Lee, J., Nicosia, M., & Lathia, J. D. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh7674 · Cited by 4
Silginer, M., Weller, M., Becher, B., Mastall, M., Weiß, T., Núñez, N. G., Kienzler, J. C., & Roth, P. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011824 · Cited by 3
Self-citationBocci, M., Lucaroni, L., Ravazza, D., Rotta, G., Prodi, E., Principi, L., Gilardoni, E., Neri, D., Cazzamalli, S., & Galbiati, A. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01707 · Cited by 3
Self-citationLuo, G., Ma, F., Yang, Y., Yang, C., Li, X., Xie, J., Xiong, K., Chen, P., Ma, K., Zhao, Z., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02699-0 · Cited by 3
Metadata
- Authors
- Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P.
- Affiliations
- University of Zurich (CH)
- ETH Zurich (CH)
- Philochem (Switzerland) (CH)
- Corresponding author
- Weiss, Tobias
- Puca, Emanuele
- Neri, Dario
- Roth, Patrick
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-10-07
- Volume
- 12
- Issue
- 564
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3092445835
- Cited by
- 133
- References
- 54
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 27 · 2023: 24 · 2022: 24 · 2021: 21 · 2020: 1
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- European Research Council (670603)
- Swiss National Science Foundation (SNF 310030_170027, 323630_164218, 310030_182003/1)
- Oncosuisse (KFS-4544-08-2018-R)
- Forschungskredit University of Zurich (FK-18-054)
- Swiss Cancer Research Foundation (MD-PhD-3558-06-2015)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- immunocytokines, glioblastoma, tumor-infiltrating lymphocytes, tumor microenvironment, inflammatory cytokines, adaptive immunity, tumor necrosis, CD4+ T cells, CD8+ T cells, tumor perfusion, immunotherapy
- MeSH terms
- Animals, Glioblastoma, Humans, Immunotherapy, Interleukin-2, Cytokines, CD8-Positive T-Lymphocytes, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.